Drugs / AV-412
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00551850 | Oct 2007 → Oct 2009 | cancer of unknown primary site, refractory malignant neoplasm | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00381654 | Oct 2006 → Dec 2009 | neoplasm | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2007-11-13 | AVEO Pharmaceuticals, Inc. | Results Preclinical Data Published in Cancer Science Show AVEO’s Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers aveooncology.com ↗
In addition, AV-412 also demonstrated significant anti-tumor effects on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib. |
| 2007-04-17 | AVEO Pharmaceuticals, Inc. | Results AVEO Presents Preclinical Efficacy Data on AV-412, A Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-resistant Lung Cancer aveooncology.com ↗
The results from the preclinical study showed that AV-412 is greater than 10 times more potent than erlotinib in genetically engineered lung tumor models with the EGFR L858R mutation, producing rapid and complete tumor regression at a daily dose of 1 mg/kg. |
| 2006-04-04 | AVEO Pharmaceuticals, Inc. | Results AV-412 Preclinical Efficacy Data Presented at AACR 2006 aveooncology.com ↗
Importantly, AV-412 also demonstrated potent anti-tumor activity against tumors that were resistant to treatment with erlotinib and gefitinib. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-11-13 | AVEO Pharmaceuticals, Inc. | Preclinical Data Published in Cancer Science Show AVEO’s Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers aveooncology.com ↗ |
| 2007-04-17 | AVEO Pharmaceuticals, Inc. | AVEO Presents Preclinical Efficacy Data on AV-412, A Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-resistant Lung Cancer aveooncology.com ↗ |
| 2006-10-23 | AVEO Pharmaceuticals, Inc. | AVEO Pharmaceuticals initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors aveooncology.com ↗ |
| 2006-04-04 | AVEO Pharmaceuticals, Inc. | AV-412 Preclinical Efficacy Data Presented at AACR 2006 aveooncology.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV 412 | “AV 412 is a potent inhibitor of human epidermal growth factor family receptor tyrosine kinases (TKIs) and represents a growing class of anti-cancer agents.” NCT00381654 ↗ |
| Known as | Mp 412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2138625 ↗ |
| Known as | MP-412 DITOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2138625 ↗ |
| Action | Inhibit | “AV 412 is a potent inhibitor of human epidermal growth factor family receptor tyrosine kinases (TKIs)” NCT00381654 ↗1“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL2138625 ↗ |
| Modality | Small molecule | — CHEMBL2138625 ↗ |
| Route | Oral | “daily oral administration of AV 412” NCT00381654 ↗ |
| Target | EGFR | “inhibitor of the EGFR-tyrosine kinase” NCT00551850 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL2138625 ↗ |